NCT04224779Active, not recruiting
Liquid Biopsies and IMAging for Improved Cancer Care
Liquid Biopsies and IMAging for Improved Cancer Care - Non Metastatic Rectal Cancer
Source: ClinicalTrials.gov · Last updated 12 Feb 2025
Brief summary (registry, in English)
The recently developed liquid biopsy technology (to obtain and characterize tumour cells and tumour components like Deoxyribonucleic acid (DNA) or Ribonucleic Acid (RNA) from a simple blood draw), in combination with advanced Magnetic Resonance Imaging techniques (MRI), can tackle the following problems in rectal cancer: 1. Assessment of tumour heterogeneity from liquid biopsies. 2. Assessment from advanced MRI feature extraction to indicate poor outcome 3. Faster assessment of therapy response in Neoadjuvant chemotherapy (NAT) for rectal cancer; 4. Detection of emerging drug/therapy resistance. This project's overall objective is to develop and validate technologies and tools to include liquid biopsies in the clinical workflow, aiming at introducing a more precise and dynamic genetic characterization of tumour at the diagnosis and during treatment phases.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 16 (actual)
- First submitted
- 8 Jan 2020
- Start date
- Feb 2021
- Primary completion date
- May 2022
- Lead sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
- Diseases
- Colorectal cancer
- NCT number
- NCT04224779
What you commit to
- Study type: Interventional
- Participants enrolled: 16
- From Feb 2021 to the primary completion date, May 2022
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patient with metastatic disease
- Symptomatic cardiac or coronary insufficiency
- Severe renal insufficiency
- Progressive active infection or any other severe medical condition
- Other cancer treated within the last 5 years except in situ cervical carcinoma or basocellular/ spinocellular carcinoma
- Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol or follow-up schedule
Other
- Pregnant or breast-feeding woman
- Unaffiliated patient to French Social Protection System
- Persons deprived of liberty or under guardianship or incapable of giving consent
Who the study is looking for
- Age ≥ 18 years old
- Histologically-confirmed diagnosis of adenocarcinoma of the rectum
- Distal part of the tumour within 2 to 12 cm of the anal margin
- Candidate for Neoadjuvant chemotherapy (NAT)
- Measurable disease (using the Recist criteria v1.1)
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1
- General condition considered suitable for radical pelvic surgery
- Adequate bone marrow, hepatic and renal function
- Willing to participate to the study, and able to give informed consent and to comply with the treatment and follow-up schedules
- Patient being able to follow all the treatment as well as the follow-ups planned in this study
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Insitut Régional du Cancer de Montpellier Coordinator of this site? Confirm its status | Montpellier | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.